Product Development

[+] larger view (PDF)

The lead project, MD05, is a synthetic bone augmentation material coated with rhGDF-5 for dental implantology and induction of bone and dental tissue regeneration for the treatment of periodontal disease.  As shown in a Phase IIa study, augmentation of the sinus floor using MD05 was successfully demonstrated.  Results of another Phase IIa study have shown evidence of favorable effects on periodontal regeneration/healing.  Scil Technology´s recent introduction of its MD08 Product Line, an adhesive paste containing a growth factor for restoration of the periodontal attachment apparatus, has shown promising pre-clinical results in various periodontitis models in dogs.  On March 7^th 2008, Scil Technology and Medtronic, Inc. entered into a Development and License Agreement covering the entire dental portfolio.

ST01 is a fully synthetic bone substrate material aiming for the treatment of lumbar, thoracic and cervical fusion and related procedures. Its superiority has been demonstrated in preclinical proof-of-concept spinal fusion and long bone defect animal models respectively.  While Minimal Invasive Surgery is advancing, Scil Technology´s recent development initiatives of its in situ forming injectable Bone Graft Biomaterials are at the forefront of this technology. 

The project portfolio is further augmented by the cartilage repair line, ST03, ST04 and ST05, which are based on a highly specific cartilage growth factor, rhCD-RAP.  These projects target repairing damaged cartilage caused by injuries related to accidents (sports, motor vehicle) or age-related degenerative cartilage lesions.  Significant improved repair of osteochondral defects and induced osteoarthritis were demonstrated in various small and large animal models.

All products are protected by Scil Technology’s patents and patent applications or by licensed patent rights.